UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES  

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or  
Section 30(h) of the Investment Company Act of 1940  

1. Name and Address of Reporting Person *  
Karachun Rita A  
(Middle)  
MERCK & CO., INC., 126 EAST LINCOLN AVENUE  
RAHWAY, NJ 07065  

2. Issuer Name and Ticker or Trading Symbol  
Merck & Co., Inc. [ MRK ]  

3. Date of Earliest Transaction (MM/DD/YYYY)  
10/28/2022  

4. If Amendment, Date Original Filed (MM/DD/YYYY)  

5. Relationship of Reporting Person(s) to Issuer  
(Verify all applicable)  
X Director  60 10% Owner  
X Officer (give title below)  Other (specify below)  
Sr. VP Fince-Global Controller  

---  

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**  

<table>
<thead>
<tr>
<th>1. Title of Security (Instr. 3)</th>
<th>2. Trans. Date</th>
<th>2A. Deemed Execution Date, if any</th>
<th>3. Trans. Code (Instr. 8)</th>
<th>4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)</th>
<th>5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>7. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>10/28/2022</td>
<td>M</td>
<td>16997</td>
<td>A $0</td>
<td>58099.972</td>
<td>D</td>
<td></td>
</tr>
<tr>
<td>Common Stock</td>
<td>10/28/2022</td>
<td>M</td>
<td>15000</td>
<td>A $0</td>
<td>73099.972</td>
<td>D</td>
<td></td>
</tr>
<tr>
<td>Common Stock</td>
<td>10/28/2022</td>
<td>S</td>
<td>31997</td>
<td>D $100.343</td>
<td>41102.972</td>
<td>D</td>
<td></td>
</tr>
</tbody>
</table>

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**  

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>$53.06</td>
<td>10/28/2022</td>
<td>M</td>
<td>16997</td>
<td>5/10/2017</td>
<td>5/9/2026</td>
<td>Common Stock</td>
<td>16997</td>
<td>$0</td>
<td>D</td>
<td></td>
</tr>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>$62.07</td>
<td>10/28/2022</td>
<td>M</td>
<td>15000</td>
<td>5/10/2017</td>
<td>5/9/2027</td>
<td>Common Stock</td>
<td>15000</td>
<td>$0</td>
<td>15875</td>
<td>D</td>
</tr>
</tbody>
</table>

Explanation of Responses:  
(1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.2800 to $100.4700, inclusive. The reporting person undertakes to provide Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.  
(2) Holdings include shares acquired in dividend reinvestment transactions.  
(4) Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.  

**Reporting Owners**  

<table>
<thead>
<tr>
<th>Reporting Owner Name / Address</th>
<th>Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>Karachun Rita A</td>
<td>Director 10% Owner</td>
</tr>
<tr>
<td>MERCK &amp; CO., INC.</td>
<td>Officer</td>
</tr>
<tr>
<td>126 EAST LINCOLN AVENUE</td>
<td>Sr. VP Fince-Global Controller</td>
</tr>
<tr>
<td>RAHWAY, NJ 07065</td>
<td></td>
</tr>
</tbody>
</table>
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.